John Michael Southern

Azadyne Ltd. is an Irish preclinical biotech company that has identified a new target within the body and a previously undrugged pathway to treat autoimmune diseases. Azadyne is based in Dublin2, IE. The company is able to selectively control natural regulatory pathways to modify specific pathogenic immune populations. The company's groundbreaking work in RNA modification has been supported by investment syndicates led by NCL. The company was founded in 2019 by Jason Rutt, Vincent Kelly, Stephen Connon, and Mike Southern to commercialize the pioneering work on the QTRT or TGT pathway carried out in Profs Kelly, Connon & Southerns labs at Trinity College Dublin.

Azadyne Ltd. is an Irish preclinical biotech company that has identified a new target within the body and a previously undrugged pathway to treat autoimmune diseases. Azadyne is based in Dublin2, IE. The company is able to selectively control natural regulatory pathways to modify specific pathogenic immune populations. The company's groundbreaking work in RNA modification has been supported by investment syndicates led by NCL. The company was founded in 2019 by Jason Rutt, Vincent Kelly, Stephen Connon, and Mike Southern to commercialize the pioneering work on the QTRT or TGT pathway carried out in Profs Kelly, Connon & Southerns labs at Trinity College Dublin.

Azadyne Ltd. is an Irish preclinical biotech company that has identified a new target within the body and a previously undrugged pathway to treat autoimmune diseases. Azadyne is based in Dublin2, IE. The company is able to selectively control natural regulatory pathways to modify specific pathogenic immune populations. The company's groundbreaking work in RNA modification has been supported by investment syndicates led by NCL. The company was founded in 2019 by Jason Rutt, Vincent Kelly, Stephen Connon, and Mike Southern to commercialize the pioneering work on the QTRT or TGT pathway carried out in Profs Kelly, Connon & Southerns labs at Trinity College Dublin.

Azadyne Ltd. is an Irish preclinical biotech company that has identified a new target within the body and a previously undrugged pathway to treat autoimmune diseases. Azadyne is based in Dublin2, IE. The company is able to selectively control natural regulatory pathways to modify specific pathogenic immune populations. The company's groundbreaking work in RNA modification has been supported by investment syndicates led by NCL. The company was founded in 2019 by Jason Rutt, Vincent Kelly, Stephen Connon, and Mike Southern to commercialize the pioneering work on the QTRT or TGT pathway carried out in Profs Kelly, Connon & Southerns labs at Trinity College Dublin.